An overview of treatment response rates to various anti-viral drugs in Pakistani Hepatitis B Virus infected patients

Virology Journal

Volumn 8, Issue , 2011, Pages

  Ali, Liaqat ^a   Idrees, Muhammad ^a   Ali, Muhammad ^a   Rehman, Irshad Ur ^a   Hussain, Abrar ^a   Afzal, Samia ^a   Butt, Sadia ^a   Saleem, Sana ^a   Munir, Saira ^a   Badar, Sadaf ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; BONE MARROW SUPPRESSION; COUGHING; DELTA AGENT HEPATITIS; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; FATIGUE; FEVER; FLU LIKE SYNDROME; GENETIC HETEROGENEITY; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION RISK; INSOMNIA; LACTIC ACIDOSIS; MAJOR DEPRESSION; MENTAL DISEASE; MIXED INFECTION; MONOTHERAPY; MYOPATHY; NEUROPATHY; NONHUMAN; PAKISTAN; PREVALENCE; REVIEW; RHINOPHARYNGITIS; SEROCONVERSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; GENETIC VARIABILITY; GENETICS; HEPATITIS B VIRUS;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS;

ANTIVIRAL AGENTS; GENETIC VARIATION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; LAMIVUDINE; PAKISTAN; POLYETHYLENE GLYCOLS;

EID: 78651364978     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-20     Document Type: Review

References (48)

1. Hepatitis B virus YMDD-motif mutations with emergence of lamivudine-resistant mutants: a threat to recovery. Z Awan M Idrees S Rafique I Rehman H Akbar S But, et al. Gastroenterology and Hepatology From Bed to Bench 2010 3 108 114
2. Hepatitis B virus infection. W Lee, N Engl J Med 1997 337 1733 1745 10.1056/NEJM199712113372406 9392700
3. Hepadnaviridae: the viruses and their replication. D Ganem RJ Schneiden, et al. Fields Virology Philadelphia: Lippincott-Raven, Knipe DM, Howely PM, Griffin DE, 2001 292 2969
4. Hepadnavirus infection requires interaction between the viral pre-s domain and a specific hepatocellular receptor. U Klingmuller H Schallen, J Virol 1993 67 7414 7422 8230462
5. Hepatitis B virus genotypes and clinical manifestation among hepatitis B carriers in Thailand. F Sugauchi A Chutaputti E Orito H Kato S Suzuki R Ueda M Mizokami, J Gastroenterol Hepatol 2002 17 671 676 10.1046/j.1440-1746.2002. 02754.x 12100612
6. Prevalence of HBV genotypes in asymptomatic carrier residents and their clinical characteristics during long-term follow-up: the relevance to changes in the HBeAg/anti-HBe system. K Ishikawa T Koyama T Masuda, Hepatol Res 2002 24 1 10.1016/S1386-6346(02)00017-7 12243786
7. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. C Westland W Delaney H Yang C Gibbs M Miller MJ Wulfsohn, Gastroenterology 2003 125 107 116 10.1016/S0016-5085(03) 00700-5 12851876
8. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. H Sumi O Yokosuka N Seki M Arai F Imazeki T Kurihara T Kanda K Fukai M Kato H Saisho, Hepatology 2003 37 19 26 10.1053/jhep.2003.50036 12500184 (Pubitemid 36042140)
9. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. E Orito M Mizokami H Sakugawa K Michitaka K Ishikawa T Ichida, et al. Hepatology 2001 33 218 223 10.1053/jhep.2001.20532 11124839
10. Prevalence of hepatitis B carriers among children in Bahawalpur urban slums. GQK Khichi MS Channar, Pak J Med Sci 2000 16 238 241
11. Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. MF Khattak N Salamat FA Bhatti TZ Qureshi, J Pak Med Assoc 2002 52 398 402 12532573
12. Epidemiologic study of chronic hepatitis B virus infection in male volunteer blood donors in Karachi, Pakistan. S Akhtar M Younus S Adil F Hassan SH Jafri, BMC Gastroenterol 2005 5 26 10.1186/1471-230X-5-26 16086833
13. Genetic variability in the precore and core promoter regions of hepatitis B virus strains in Karachi. Z Abbas R Muzaffar A Siddiqui SAA Naqvi SAH Rizvi, BMC Gastroenterol 2006 6 20 10.1186/1471-230X-6-20 16863587
14. Hepatitis A. RK Gilroy S Mukherjee, Kanas Med Centre 2008
15. Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine. N Cammack P Rouse CL Marr PJ Reid RE Boehme JA Coates CR Penn JM Cameron, Biochem Pharmacol 1992 43 2059 2064 10.1016/0006-2952(92)90162-C 1318048
16. Lamivudine as initial treatment for chronic hepatitis B in the United States. JL Dienstag ER Schiff TL Wright RP Perrillo HW Hann Z Goodman, et al. N Engl J Med 1999 341 1256 1263 10.1056/NEJM199910213411702 10528035
17. A one year trial of lamivudine for chronic hepatitis B. CL Lai RW Chine NWY Leung TT Chang R Guan DI Tai, et al. N Engl J Med 1998 339 61 68 10.1056/NEJM199807093390201 9654535
18. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. MF Yuen DY Fong DK Wong JC Yuen J Fung CL Lai, Hepatology 2007 46 1695 1703 10.1002/hep.21939 18027877
19. Treatment of HBV and HDV co-infection using lamivudine. H Qureshi A Arif E Alam, J Ayub Med Coll Abbottabad 2009 21 1 3 20524456
20. Triple Hepatitis: Frequency and Treatment Outcome of co/super-Infection of Hepatitis C and D Among Patients of Hepatitis B. BF Zuberi S Afsar MS Quraishy, J Coll Physicians Surg Pak 2008 18 404 407 18760062
21. Treatment of chronic Hepatitis B with Lamivudine. N Khokhar ML Gill AY Alam, J Coll Physicians Surg Pak 2005 15 78 80 15730830
22. Antiviral treatment for chronic hepatitis B virus infection-immune modulation or viral suppression? EHCJ Buster HLA Janssen, The Journal of Medicine 2006 64 175 185
23. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. AS Lok CL Lai N Leung GB Yao ZY Cui ER Schiff, et al. Gastroenterology 2003 125 1714 1722 10.1053/j.gastro.2003.09.033 14724824
24. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. JM Pawlotsky G Dusheiko A Hatzakis D Lau G Lau TJ Liang, et al. Gastroenterology 2008 134 405 415 10.1053/j.gastro.2007.11.036 18242209
25. Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B. MJ Sonneveld HLA Janssen, Curr Hepatitis Rep 2010 9 91 98 10.1007/s11901-010-0041-7
26. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. T Chang RG Gish R de-Man A Gadano J Sollano Y Chao, et al. N Engl J Med 2006 354 1001 10 10.1056/NEJMoa051285 16525137
27. Pegylated interferons for chronic hepatitis B. A Craxi WG Cooksley, Antiviral Res 2003 60 87 89 10.1016/j.antiviral.2003.08.015 14638403
28. Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. T Chang DJ Suh, Hepatol Int 2008 2 19 S27 10.1007/s12072-008-9059-0 (Pubitemid 351593899)
29. Effect of interferon-a on hepatits B viral antigen expression in primary hepatocyte culture. JYN Lau VG Bain NV Naomov HM Smith GJ Alexander R Williams, Hepatology 1991 14 9759
30. Interferon monotherapy in chronic hepatitis B. R Guan, J Gastroenterol Hepatol 2000 15 34 40 10.1046/j.1440-1746.2000.02101.x (Pubitemid 30435734)
31. Efficacy of Interferon therapy in patients of chronic hepatitis B viral infection treated at MH Rawalpindi. MA Naeem I Khan J Waris M Usman, Professional Med J 2008 15 380 386
32. Treatment outcome in patients of hepatitis B with hepatitis D: Experience of 4 years at a tertiary care centre in Pakistan. BF Zuberi MS Quraishy S Afsar N Akhtar A Kumar SK Dodani, J Coll Physicians Surg Pak 2007 17 320 322 17623577
33. Short-term intravenous interferon therapy for chronic hepatitis B. H Okushin T Ohnishi K Morii K Uesaka S Yuasa, World J Gastroenterol 2008 14 3038 3043 10.3748/wjg.14.3038 18494055
34. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. WG Cooksley T Piratvisuth SD Lee V Mahachai YC Chao T Tanwandee A Chutaputti WY Chang FE Zahm N Pluck, J Viral Hepat 2003 10 298 305 10.1046/j.1365-2893.2003.00450.x 12823597
35. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. H Okamoto F Tsuda H Sakugawa RI Sastrosoewinjo M Imai Y Miyakawa M Mayumi, J Gen Virol 1988 69 2575 2583 10.1099/0022-1317-69-10- 2575 3171552
36. New complex recombinant genotype of hepatitis B virus identified in Vietnam. T Huy T Ngoc K Abe, J Virol 2008 82 5657 5663 10.1128/JVI.02556-07 18353958
37. Molecular and phylogenetic analyses suggest an additional.Hepatitis B virus genotype ''I''. H Yu Q Yuan SX Ge HY Wang YL Zhang QR Chen J Zhang PJ Chen NS Xia, PLoS One 2010 5 9297 10.1371/journal.pone.0009297
38. Pattern and Molecular Epidemiology of Hepatitis B virus genotypes circulating in Pakistan. Z Awan M Idrees I Amin, et al. Infect Genet Evol 2010 10 1242 1246 10.1016/j.meegid.2010.08.006 20727423
39. Hepatitis B virus genotypes, subgenotypes, precore, and basal core promoter mutations in the two largest provinces of Pakistan. CS Ahmed ZH Wang Z Bin JJ Chen M Kamal JL Hou, J Gastroenterol Hepatol 2009 24 569 73 10.1111/j.1440-1746.2008.05642.x 19368634
40. Hepatitis B virus subgenotypes D1 and D3 are prevalent in Pakistan. S Baig A Siddiqui R Chakravarty T Moatter, BMC Research Notes 2009 2 1 10.1186/1756-0500-2-1 19121226
41. Prevalence of Hepatitis B virus genotype D in females in Karachi, Pakistan. S Noorali ST Hakim D McLean SU Kazmi O Bagasra, J Infect Developing Countries 2008 2 373 378
42. Seroprevalence of hepatitis B and C genotypes among yung apparently healthy females of Karachi-Pakistan. ST Hakim SU Kazmi O Bagasra, Libyan J Med 2008 3 66 70 AOP: 071123 10.4176/071123
43. Common Genotypes of Hepatitis B virus prevalent in Injecting drug abusers (addicts) of North West Frontier Province of Pakistan. MM Alam SZ Zaidi S Shaukat S Sharif M Angez A Naeem, et al. Virology J 2007 4 63 10.1186/1743-422X-4-63 (Pubitemid 47036613)
44. The association of complex liver disorders with HBV genotypes prevalent in Pakistan. S Baig AA Siddiqui W Ahmed H Qureshi A Arif, Virology J 2007 4 128 10.1186/1743-422X-4-128 (Pubitemid 351169929)
45. Hepatitis B genotypes and the response to interferon therapy. JH Kao NH Wu PJ Chen MY Lai DS Chen, J Hepatol 2000 33 998 1002 10.1016/S0168-8278(00) 80135-X 11131465
46. HBV genotype B is associated with better response to interferon therapy in HBeAg-positive chronic hepatitis than genotype C. CT Wai CJ Chu M Hussain AS Lok, Hepatology 2002 36 1425 30 12447868
47. Peginterferon alfa 2b and lamivudine combination therapy compared withpeginterferon alfa 2b for chronic HBeAg positive hepatitis B: randomized controlled trial in 307 patients. HLA Janssen H Senturk S Zeuzem U Akarka Y Cakalluglu K Simon, et al. Hepatology 2003 38 1323
48. Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H. A Erhardt T Gobel A Ludwig, J Med Virol 2009 81 1716 1720 10.1002/jmv.21588 19697400